- Home
- UPXI vs PACB Comparison
UPXI vs PACB Comparison
Compare UPXI & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- PACB
- Stock Information
- Founded
- UPXI 2018
- PACB 2000
- Country
- UPXI United States
- PACB United States
- Employees
- UPXI N/A
- PACB N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- UPXI Health Care
- PACB Industrials
- Exchange
- UPXI Nasdaq
- PACB Nasdaq
- Market Cap
- UPXI 356.9M
- PACB 364.2M
- IPO Year
- UPXI 2021
- PACB 2010
- Fundamental
- Price
- UPXI $5.22
- PACB $1.47
- Analyst Decision
- UPXI
- PACB Buy
- Analyst Count
- UPXI 0
- PACB 9
- Target Price
- UPXI N/A
- PACB $2.06
- AVG Volume (30 Days)
- UPXI 5.1M
- PACB 9.7M
- Earning Date
- UPXI 05-16-2025
- PACB 08-06-2025
- Dividend Yield
- UPXI N/A
- PACB N/A
- EPS Growth
- UPXI N/A
- PACB N/A
- EPS
- UPXI N/A
- PACB N/A
- Revenue
- UPXI $16,562,327.00
- PACB $152,357,000.00
- Revenue This Year
- UPXI $299.03
- PACB $3.33
- Revenue Next Year
- UPXI N/A
- PACB $18.52
- P/E Ratio
- UPXI N/A
- PACB N/A
- Revenue Growth
- UPXI 1378.83
- PACB N/A
- 52 Week Low
- UPXI $1.90
- PACB $0.85
- 52 Week High
- UPXI $22.57
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- UPXI 46.53
- PACB 61.70
- Support Level
- UPXI $2.73
- PACB $1.42
- Resistance Level
- UPXI $6.57
- PACB $1.53
- Average True Range (ATR)
- UPXI 0.66
- PACB 0.10
- MACD
- UPXI 0.35
- PACB 0.01
- Stochastic Oscillator
- UPXI 77.74
- PACB 71.00
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.